Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
2022 · Nature · 126 citations
https://doi.org/10.1038/s41586-022-05066-5
C
Catrin Lutz
Oncode Institute(NL)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
86
Papers
782
Citations
12
h-index
13
i10-index
Catrin Lutz is an academic researcher from Oncode Institute. The author has contributed to research in topics: Fibroblast Growth Factor Research & Cancer Research and Treatments & Eosinophilic Disorders and Syndromes. The author has an h-index of 12, co-authored 74 publications.
ORCID: 0009-0002-5152-6785Papers by this author
works<i>In situ</i> CRISPR‐Cas9 base editing for the development of genetically engineered mouse models of breast cancer
2020 · The EMBO Journal · 60 citations
https://doi.org/10.15252/embj.2019102169
Mechanisms that clear mutations drive field cancerization in mammary tissue
2024 · Nature · 27 citations
https://doi.org/10.1038/s41586-024-07882-3
Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity
2023 · EMBO Molecular Medicine · 25 citations
https://doi.org/10.15252/emmm.202317737
Emerging roles of cohesin-STAG2 in cancer
2024 · Oncogene · 6 citations
https://doi.org/10.1038/s41388-024-03221-y
Fasting boosts breast cancer therapy efficacy via glucocorticoid activation
2025 · Nature · 2 citations
https://doi.org/10.1038/s41586-025-09869-0
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat